

# Uncertainties for Cochrane Airways

## Priority-Setting Group to rank

Here are 99 uncertainties to consider and rank. Please pick out your top ten and add to the table at the bottom of this document. There is an accompanying document giving some information about the burden of disease and a [glossary](#). The glossary is currently a google doc – please add a comment or email Emma with any feedback or extra words you would like to add and we will add a definition.

We have endeavored to show where there are Cochrane reviews relating to the topic and the search date (in parenthesis) as an indication of how up-to-date the review is. We have not indicated whether there are any further eligible studies. There may also be more than one possible Cochrane review for a particular uncertainty - or a review may need expanding or changing to meet the public's needs. We can explore some of this when we have the top uncertainties.

The following framework can be used to help you assess each question and help you think beyond your own personal experience. We hope this will help you in your thinking, however it is OK to vote for what you think of as important. You are only representing yourself and not everyone with a respiratory condition. These decisions are subjective. This group is much broader and more experience and the process is more transparent than what has happened previously in Airways! At the next meeting we can look at the rankings and see if there are any uncertainties that didn't get picked that we think should be retained or moved up e.g. if they are important to people not represented on this group.

Cochrane Airways Priority-setting group uncertainty assessment framework		
Addressing this question responds to a problem that is of large burden...	...to society as a whole	
	...to healthcare systems	
	...to individuals	
Are there up-to-date Cochrane Reviews on this topic?		
Addressing this question is expected to positively impact equity (e.g. the avoidable or unfair differences in health care among groups of people) in health		

Group	Question	Related Cochrane Reviews (search date)
Triggers	1. Interventions to help identify asthma triggers	
	2. Interventions to avoid pulmonary triggers in sarcoidosis e.g. air pollution, chemicals, infection	
	3. Interventions to avoid triggers for asthma (2)	<p><a href="#">Individual-level interventions to reduce personal exposure to outdoor air pollution and their effects on long-term respiratory conditions</a> (protocol)</p> <p><a href="#">Interventions for autumn exacerbations of asthma in children</a> (December 2017)</p> <p><a href="#">Pet allergen control measures for allergic asthma in children and adults</a> (September 2008)</p> <p><a href="#">Mono- and multi-faceted inhalant and/or food allergen reduction interventions for preventing asthma in children at high risk of developing asthma</a> (January 2011)</p> <p><a href="#">House dust mite control measures for asthma</a> (July 2011)</p> <p><a href="#">Feather versus non-feather bedding for asthma</a> (February 2009)</p>
	4. Interventions to avoid triggers in COPD	<p><a href="#">Individual-level interventions to reduce personal exposure to outdoor air pollution and their effects on long-term respiratory conditions</a> (protocol)</p>
	5. New evidence mapping exercise for asthma (4)	

Evidence mapping	6. New evidence mapping exercise for interventions for exercise induced asthma	
	7. New evidence mapping exercise for biologics for asthma (3)	
	8. New evidence mapping exercise for COPD (2)	
	9. New evidence mapping exercise for interventions for bronchiolitis obliterans	
	10. New evidence mapping exercise for interventions to prevent asthma (e.g. vitamin D, allergen exposure, childhood exposure to air pollution etc.)	
	11. New evidence mapping exercise for Idiopathic Pulmonary Fibrosis (IPF)	
	12. New evidence mapping exercise for novel interventions to treat respiratory infections in people with asthma (e.g. interferon treatment)	
	13. New evidence mapping exercise for obstructive sleep apnea (OSA)	
	14. New evidence mapping exercise for pulmonary hypertension	
	15. New evidence mapping exercise for sarcoidosis (2)	
	16. Interventions for early/mild pulmonary disease associated with sarcoid, including allied health therapies	
	17. Interventions to treat early/mild bronchiectasis	

Treatments (interventions) - drugs	18. Antihistamines for asthma	<a href="#">Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children</a> (May 2010)
	19. Inhaled therapies for bronchiectasis	<a href="#">Combination inhaled corticosteroids and long-acting beta-agonists for children and adults with bronchiectasis</a> (March 2014)  <a href="#">Interventions for bronchiectasis: an overview of Cochrane systematic reviews</a> (2015)  <a href="#">Inhaled corticosteroids for bronchiectasis</a> (June 2017)  <a href="#">Long-acting beta2-agonists for bronchiectasis</a> (August 2010)  <a href="#">Short acting beta2-agonists for bronchiectasis</a> (May 2008)
	20. Interventions for small airway inflammation and chronic rhinosinusitis	
	21. Interventions to reduce mucus production in bronchiectasis	We have 2 separate reviews on hyperosmolar and mucolytic agents, but we recommend to begin with a new review including both.
	22. Long term effects of inhaled steroids (ICS) and short-acting beta2-agonists (SABA) in asthma (2)	-
	23. Long term effects of oral and intravenous (IV) antibiotics in bronchiectasis	<a href="#">Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults</a> (February 2014)
	24. Long-acting muscarinic antagonists (LAMA) in addition to inhaled corticosteroids (ICS) and leukotriene receptor antagonists (LTRA) vs ICS and LTRA alone in asthma	-

	25. Network meta-analysis of antibiotics options in acute COPD (i.e. antibiotics for exacerbations rather than prophylaxis)	-
	26. Network meta-analysis focused on adverse events of treatments for asthma (would be methodologically very challenging).	<a href="#">Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews</a> (September 2013)  <a href="#">Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews</a> (May 2012)
	27. Interventions (other than spacers) to reduce dysphonia (effects on the voice) associated with inhaler use	-
	28. Safety of long-acting muscarinic antagonists (LAMAs) for asthma in pregnancy	<a href="#">Interventions for managing asthma in pregnancy</a> (2014)
	29. Short and long term adverse events associated with ICS/combined inhaler use	<a href="#">Inhaled steroids with and without regular salmeterol for asthma: serious adverse events</a> (October 2018)  <a href="#">Inhaled steroids with and without regular formoterol for asthma: serious adverse events</a> (February 2019)  <a href="#">Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events</a> (august 2011)  <a href="#">Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews</a> (September 2013)

		<a href="#">Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews</a> (May 2012)
	30. Stopping/withdrawing inhaled asthma medication	<a href="#">Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids</a> (April 2015)  <a href="#">Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids</a> (April 2015)
	31. Sub-cutaneous immunotherapy for asthma	<a href="#">Injection allergen immunotherapy for asthma</a> (August 2005)
	32. Update “Antibiotics for exacerbations of chronic obstructive pulmonary disease” ( <a href="http://dx.doi.org/10.1002/14651858.CD010257.pub2">http://dx.doi.org/10.1002/14651858.CD010257.pub2</a> , September 2018) review with new evidence (2)	
	33. Update “Anti-IL5 therapies for asthma” ( <a href="http://dx.doi.org/10.1002/14651858.CD010834.pub3">http://dx.doi.org/10.1002/14651858.CD010834.pub3</a> , March 2017 ) review with latest evidence (3)	
	34. Update “Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease: a systematic review and network meta-analysis” ( <a href="http://dx.doi.org/10.1002/14651858.CD012620.pub2">http://dx.doi.org/10.1002/14651858.CD012620.pub2</a> , April 2018 ) with new evidence	
	35. Update “Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease” <a href="http://dx.doi.org/10.1002/14651858.CD001287.pub6">http://dx.doi.org/10.1002/14651858.CD001287.pub6</a> , April 2019) with new evidence (2)	

	36. Update “Omalizumab for asthma in adults and children” ( <a href="http://dx.doi.org/10.1002/14651858.CD003559.pub4">http://dx.doi.org/10.1002/14651858.CD003559.pub4</a> , June 2013) with latest evidence (3)	
	37. Update “Prophylactic antibiotic therapy for chronic obstructive pulmonary disease” ( <a href="http://dx.doi.org/10.1002/14651858.CD009764.pub3">http://dx.doi.org/10.1002/14651858.CD009764.pub3</a> , July 2018) with new evidence (2)	
Treatments (interventions) – non-drug	38. Interventions to promote physical activity in people with exercise-induced asthma (2)	<a href="#">Beta2-agonists for exercise-induced asthma</a> (2013)  <a href="#">Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction</a> (October 2008)
	39. Pulmonary rehabilitation for sarcoidosis	<a href="#">Telerehabilitation for chronic respiratory disease</a> (protocol stage) (we think they will include participants with sarcoid, if found, although obviously this condition isn't the focus of the review)
	40. Update “Shared decision-making for people with asthma” ( <a href="http://dx.doi.org/10.1002/14651858.CD012330.pub2">http://dx.doi.org/10.1002/14651858.CD012330.pub2</a> , November 2016 ) with new evidence	
	41. Update “Speech and language therapy for management of chronic cough” ( <a href="http://dx.doi.org/10.1002/14651858.CD013067.pub2">http://dx.doi.org/10.1002/14651858.CD013067.pub2</a> , February 2019 ) review with new evidence	
	42. Interventions to improve uptake of and adherence to personalized asthma action plans	<a href="#">Personalized asthma action plans for adults with asthma</a> (September 2016)



	43. Interventions to improve engagement/adherence to routine care for parents of children with long term respiratory conditions	-
	44. Interventions to improve engagement with self-management and education for people with IPF	-
	45. Interventions to improve education of parents of children with asthma	-
	46. Breathing/relaxation exercises for COPD	<a href="#">Breathing exercises for chronic obstructive pulmonary disease</a> (October 2011)  <a href="#">Active mind-body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with chronic obstructive pulmonary disease</a> (July 2017)  <a href="#">Tai Chi for chronic obstructive pulmonary disease (COPD)</a> (September 2015)
	47. Cognitive behavioral therapy for COPD	<a href="#">Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease</a> (2018)  <a href="#">Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease</a> (2017)
	48. Effects of manual techniques vs intermittent positive pressure breathing vs breathing exercises in bronchiectasis	<a href="#">Airway clearance techniques for bronchiectasis</a> (November 2015)  <a href="#">Physical training for bronchiectasis</a> (protocol)
	49. Pulmonary rehabilitation for COPD/asthma/bronchiectasis/IPF	<a href="#">Factors influencing referral to and uptake and attendance of pulmonary rehabilitation for chronic obstructive pulmonary disease: a qualitative evidence synthesis of the</a>

		<p><a href="#">experiences of service users, their families, and healthcare providers</a> (protocol stage)</p> <p><a href="#">Interventions to promote referral, uptake and adherence to pulmonary rehabilitation for people with chronic obstructive pulmonary disease (COPD)</a> (protocol stage)</p> <p>Review closed <a href="#">Pulmonary rehabilitation for chronic obstructive pulmonary disease</a></p> <p><a href="#">Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease</a> (October 2015)</p> <p><a href="#">Pulmonary rehabilitation using minimal equipment for people with chronic obstructive pulmonary disease (COPD)</a> (protocol stage)</p> <p><a href="#">Telerehabilitation for chronic respiratory disease</a> (protocol stage)</p> <p><a href="#">Pulmonary rehabilitation for interstitial lung disease</a></p> <p><a href="#">Physical training for asthma</a> (June 2014)</p> <p>Pulmonary rehabilitation for adults with asthma (Protocol in preparation)</p>
	50. Interventions to promote referral and uptake of pulmonary rehabilitation for IPF	-
	51. Psychological support in management of COPD	<p><a href="#">Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease</a> (2018)</p> <p><a href="#">Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease</a> (2017)</p>

	52. Role of health coaching/motivational interviewing in COPD	-
Treatments (interventions) – mixed	53. Interventions for difficult to treat non-atopic asthma (2)	-
	54. Interventions that improve symptoms/quality of life/maintaining normal activities (rather than focusing on exacerbation reduction alone) for asthma	-
	55. Interventions to improve mucus expectoration in bronchiectasis (2)	<a href="#">Airway clearance techniques for bronchiectasis</a> (November 2015) <a href="#">Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis</a> (February 2017) <a href="#">Inhaled hyperosmolar agents for bronchiectasis</a> (April 2014)
	56. Interventions to maintain normal activities for children with asthma/avoid exercise induced asthma (so they can enjoy normal play)	<a href="#">Beta2-agonists for exercise-induced asthma</a> (2013)
	57. Interventions for severe cough in bronchiectasis (2)	-
	58. Interventions tailored for older people with asthma	
	59. Interventions to improve cough in people with interstitial lung disease (ILD)	-
	60. Personalized/targeted therapies for ILD guided by genotype or phenotype	-

	61. Update “Personalized asthma action plans for adults with asthma” ( <a href="http://dx.doi.org/10.1002/14651858.CD011859.pub2">http://dx.doi.org/10.1002/14651858.CD011859.pub2</a> ) with latest evidence	
	62. Update Interventions for bronchiectasis: an overview of Cochrane systematic reviews ( <a href="http://dx.doi.org/10.1002/14651858.CD010337.pub2">http://dx.doi.org/10.1002/14651858.CD010337.pub2</a> )	
Prognosis	63. Causes/prognosis for adult-onset asthma (2)	-
	64. Prognosis review for asthma (consider socio-economic status, exposure to air pollution)	-
	65. Prognosis review for bronchiectasis: what factors are associated with worsening? (2)	-
	66. Prognosis review for COPD (2)	-
	67. Prognosis review in primary ciliary dyskinesia (PCD)	-
	68. Prognosis review to identify markers associated with worsening asthma/fixed airflow obstruction (2)	-
	69. Prognosis review to identify markers associated with worsening asthma/development of new respiratory conditions	-
	70. Long term prognosis of bronchopulmonary dysplasia associated with prematurity	-
Diagnosis	71. Diagnostic criteria for exacerbations	-

	72. Diagnostic test accuracy review (DTA) review for early diagnosis of sarcoid	-
	73. Screening (including genetic screening of relatives) for ILD	-
	74. Interventions to identify extra-pulmonary complications of bronchiectasis, including osteoporosis	-
	75. Interventions to identify the cause of exacerbations in bronchiectasis	-
	76. Interventions to help health care professionals identify at-risk patients with asthma/other long term respiratory conditions	-
Prevention and cures	77. Interventions that can prevent/cure asthma (rather than treatment symptoms alone)	<a href="#">Vitamin D supplementation in pregnant or breastfeeding women or young children for preventing asthma</a> (Protocol)
	78. Interventions to prevent asthma deaths (e.g. how to identify an at-risk patient)	-
	79. Interventions to prevent/treat recurrent candida infections associated with antibiotic use	-
	80. Interventions to prevent/manage chronic hydropneumothorax	-
	81. Interventions to prevent infections in bronchiectasis	<a href="#">Intermittent prophylactic antibiotics for bronchiectasis</a> (Protocol)  <a href="#">Macrolide antibiotics for bronchiectasis</a> (January 2018)

		<a href="#">Prolonged antibiotics for bronchiectasis in children and adults</a> (February 2014)  <a href="#">Dual antibiotics for bronchiectasis</a> (October 2017)  <a href="#">Oral versus inhaled antibiotics for bronchiectasis</a> (March 2018)  <a href="#">Head-to-head trials of antibiotics for bronchiectasis</a> (April 2018)
	82. Interventions to prevent infections in COPD	<a href="#">Prophylactic antibiotic therapy for chronic obstructive pulmonary disease</a> (July 2018)  <a href="#">Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease</a> (February 2019)  <a href="#">Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis (Protocol)</a>
	83. Interventions to prevent/cure IPF (2)	-
	84. Interventions to prevent bronchiectasis	-
	85. Interventions to prevent bacterial infection in hydropneumothorax	-
	86. Interventions to reduce infectious exacerbations of COPD	<a href="#">Prophylactic antibiotic therapy for chronic obstructive pulmonary disease</a> (July 2018)  <a href="#">Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease</a> (February 2019)

		<a href="#">Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis (Protocol)</a>
Service provision	87. Care pathways to improve access to specialist respiratory services	<a href="#">Clinical pathways for chronic cough in children</a> (January 2014)
	88. Discharge planning for people with IPF	-
	89. Diagnostic test accuracy (DTA) review of screening interventions for COPD	-
	90. Improving access to routine reviews for respiratory conditions for adults and children with mental health problems and learning disability	-
	91. Implications/outcomes of routine sharing of medical health records with patients	-
	92. Interventions to improve awareness and knowledge of bronchiectasis health care professionals (4)	-
	93. Interventions to improve awareness and knowledge of primary ciliary dyskinesia (PCD) and bronchiectasis health care professionals (2)	-
	94. What is the role of a practice nurse caring for someone with bronchiectasis?	<a href="#">Nurse-led versus doctor-led care for bronchiectasis</a> (March 2018)
	95. Interventions for improved transition of care (handover process from one group of healthcare professionals to another e.g. from hospital care to GP care after discharge) between health care professionals for people with long term respiratory conditions	<a href="#">Caseworker-assigned discharge plans to prevent hospital readmission for acute exacerbations in children with chronic respiratory illness</a> (November 2017)

	96. Routine monitoring of long term respiratory conditions to ensure treatment regimen is appropriate	<a href="#">Exhaled nitric oxide levels to guide treatment for adults with asthma</a> June 2016) <a href="#">Exhaled nitric oxide levels to guide treatment for children with asthma</a> (June 2016)
	97. Timing and content of routine reviews for bronchiectasis	-
Other	98. Development of core outcome sets for biologics for asthma that are not focused solely on exacerbation reduction	-
	99. Interventions to safeguard children with asthma when parents continue to expose them to second-hand smoke	-



Please add your overall top 10 here. Simply copy and paste

Your name:

Rank	Uncertainty
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	